RenalGuard is designed to reduce the toxic effects of contrast media on the kidneys, which may lead to a reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients. RenalGuard Therapy is based on existing published literature, including the PRINCE study, which supports the theory that creating and maintaining a high urine output through the kidneys allows the body to eliminate contrast, reducing its toxic effects rapidly.
Demonstration of how RenalGuard can help reduce the chance of kidney injury in high risk patients.
© Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.